Cargando…

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

SIMPLE SUMMARY: Positron emission tomography/computed tomography (PET/CT) has an increasingly relevant role in the management of oncological patients. It consists of the administration of a radioactive molecule (tracer) which localizes in tumour cells due to specific cellular features (e.g., a recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzo, Alessio, Dall’Armellina, Sara, Pizzuto, Daniele Antonio, Perotti, Germano, Zagaria, Luca, Lanni, Valerio, Treglia, Giorgio, Racca, Manuela, Annunziata, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406909/ https://www.ncbi.nlm.nih.gov/pubmed/36011032 http://dx.doi.org/10.3390/cancers14164039

Ejemplares similares

Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review
por: Rizzo, Alessio, et al.
Publicado: (2023)

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
por: Rizzo, Alessio, et al.
Publicado: (2023)

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
por: Rizzo, Alessio, et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
por: Treglia, Giorgio, et al.
Publicado: (2019)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Intracoronary Adenosine versus Intravenous Adenosine during Primary PCI for ST-Elevation Myocardial Infarction: Which One Offers Better Outcomes in terms of Microvascular Obstruction?
por: Doolub, Gemina, et al.
Publicado: (2013)

Neoangiogenesis in prostate cancer
por: Łuczyńska, Elżbieta, et al.
Publicado: (2013)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Predictors of Bone Metastases at (68)Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence
por: Rovera, Guido, et al.
Publicado: (2022)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
por: Deberle, Luisa M., et al.
Publicado: (2020)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001
por: Stenberg, Vilde Yuli, et al.
Publicado: (2022)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses
por: Annunziata, Salvatore, et al.
Publicado: (2020)

Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Rizzo, Alessio, et al.
Publicado: (2023)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
por: Tschan, Viviane J., et al.
Publicado: (2021)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
por: Hoshi, Seiji, et al.
Publicado: (2023)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Neoangiogenesis of gastric submucosa-invasive adenocarcinoma
por: Sasaki, Hanae, et al.
Publicado: (2018)

An unusual case of apical myocarditis: a case report
por: Das, Arka, et al.
Publicado: (2020)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

The Evolving Concepts of Haemodynamic Support: From Pulmonary Artery Catheter to Echocardiography and Theragnostics
por: Figueiredo, Antonio, et al.
Publicado: (2011)

Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series
por: Brada, Muriel D., et al.
Publicado: (2022)

Myocardial Inflammation—Are We There Yet?
por: Greulich, Simon, et al.
Publicado: (2015)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer
por: Duffy, John P, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_lnbdmu01cu64g5anrqkatdqauc